Risankizumab and Certolizumab Pegol Dual-Targeted Therapy for Crohn’s Disease and Axial Spondyloarthritis: A Case Report
DTT using risankizumab and certolizumab pegol is effective in CD and axSpA without serious adverse events in our patient. Combining biologicals that target specific pathways in immune-mediated diseases promises excellent potential in CD associated with extraintestinal manifestations.
Authors
- Diego Kyburz (ORCID: https://orcid.org/0000-0002-9560-109X)
- Petr Hrúz (ORCID: https://orcid.org/0000-0003-2767-0445)
- Jan Hendrik Niess (ORCID: https://orcid.org/0000-0001-6902-5650)
- Anouk Lehmann
- Juerg Vosbeck
Institutions
- University of Basel (CH)
- University Hospital of Basel (CH)
Publication Details
- Journal
- Case Reports in Gastroenterology
- Published
- 2024-12-24
- DOI
- https://doi.org/10.1159/000542759
- Citations
- 1
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.55